

Methodology Note Supporting the Disclosure Report for Transfers of Value In 2025

This report covers the disclosure ToV from 1st January 2025 to 31st December 2025.

This note describes the methods used by Veriton Pharma Limited in the UK to meet its obligations and the requirements for disclosing payments and Transfers of Value (ToV) to Healthcare Professionals (HCPs), Other Relevant Decision Makers (ORDMs) Healthcare Organisations (HCOs) and patient organisations as outlined in the ABPI Code of Practice for the Pharmaceutical Industry.

Veriton Pharma Ltd, BTG Specialty Pharmaceuticals (Protherics Medical Development Ltd) and SERB Specialty Pharmaceuticals are three separate companies and financial entities in the SERB Pharmaceuticals group corporate umbrella. During 2025 The SERB group acquired the company, Y-mAbs Therapeutics, which is now also part of the SERB group. Whilst these 4 companies remain separate, the 2025 UK disclosures for these four companies are being disclosed under the current existing disclosure portal for Veriton Pharma Ltd, for transparency to ensure all data is easily accessible and displayed clearly in one place.

March 2026

Veriton Pharma Ltd.

Unit 16, Trade City, Avro Way. Brooklands Business Park.

Weybridge, Surrey, KT13 0YF

Date of Preparation: March 2026

Contents

- 1 Definitions**
 - 1.1 Recipients
 - 1.2 Kind of Transfer of Value (HCP)
 - 1.2.1 Fees for service and consultancy
 - 1.2.2 Payments made to consultants in relation to market research
 - 1.2.3 Sponsorship of HCPs/ORDMs for attendance at meetings
 - 1.2.4 Sponsorship of HCOs for third party events
 - 1.2.5 Grants and Donations
- 2 Disclosures scope**
 - 2.1 Products concerned
 - 2.2 Companies concerned
 - 2.3 Excluded ToVs
 - 2.4 ToVs to date
 - 2.5 Direct ToVs
 - 2.6 Indirect ToVs
 - 2.7 Non monetary ToV
 - 2.8 ToVs in case of partial attendances or cancellation and refund
 - 2.9 Cross border activities
 - 2.10 Research and Development
- 3 Specific considerations**
 - 3.1 Country unique identifier
 - 3.2 Self incorporated HCP
 - 3.3 Multi-year agreements
 - 3.4 Country specificities
 - 3.5 Quality check
- 4 Data Protect Legal Basis**
 - 4.1 Consent collection
 - 4.2 Legitimate interests
- 5 Form of disclosure**
 - 5.1 Date of publication
 - 5.2 Disclosure platform
 - 5.3 Disclosure language
- 6 Disclosure Financial Data**
 - 6.1 Currency
 - 6.2 VAT
 - 6.3 Calculation rules
- 7 Additional Information**

1. Definitions

1.1 Recipients

Healthcare Professional (HCP)

HCP's include members of the medical, dental, pharmacy and nursing professions and any other person who during their activities may administer, prescribe, purchase, recommend or supply a medicine.

1.2 Kind of Transfer of Value (ToV)

The term transfer of value means a direct or indirect ToV, whether in cash, in kind or otherwise, made for promotional purposes or otherwise, in connection with the sale or development of licensed medicines.

1.2.1 Fees for service and consultancy and associated related expenses agreed in the fee for service/consultancy contract.

Veriton Pharma pays fair market value fees for the provision of services provided by HCPs/ORDMs. These services include chairing or speaking at meetings arranged by the company. This service provision is documented and agreed via a consultancy/speaker agreement and the fees/associated expenses are disclosed. Fees paid to HCOs for the provision of a service (e.g. consultancy or speaker fees) are reported as fee for service against the relevant HCO for 2025.

1.2.2 Payments made to consultants in relation to market research where the identity of the participants is known to Veriton Pharma.

Veriton did not make any such ToVs for market research in 2025 where the identity of the participants was known.

1.2.3 Sponsorship of HCPs/ORDMs for attendance at meetings (including registration fees and associated expenses in the form of travel and accommodation) This service provision is documented and agreed via a consultancy/speaker agreement and the fees/associated expenses are disclosed.

1.2.4 Sponsorship of HCOs for third party events (congress for example) in exchange for promotional stand or symposium slots. This service provision is documented and agreed via a sponsorship agreement .

1.2.5 Grants and donations. Veriton companies make grant payments to third parties without consideration of any kind of return in exchange for such a payment. Veriton companies grant payments made to Patient Organisations can be found in the following locations:

<https://www.veritonpharma.com/about-us/disclosures/>

1.3 Healthcare Organisation (HCO)

HCO means either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university, or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more HCPs or other relevant decision makers provide

services.

1.4 Other Relevant Decision Maker (ORDM)

ORDMs particularly include those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not HCPs.

2. Disclosures Scope

2.1 Products concerned

Veriton will collect, report and disclose all ToVs with HCPs/HCPs in relation to prescription only medicine as described within the Code and will also include over-the-counter medicines related ToVs

2.2 Companies concerned

- Veriton Pharma Ltd,
- BTG Specialty Pharmaceuticals (Protherics Medical Development Ltd)
- SERB Specialty Pharmaceuticals
- Y-mAbs Therapeutics

Veriton Pharma Ltd, BTG Specialty Pharmaceuticals (Protherics Medical Development Ltd) and SERB Specialty Pharmaceuticals are three separate companies and financial entities in the SERB Pharmaceuticals group corporate umbrella. During 2025 The SERB group acquired the company, Y-mAbs Therapeutics, which is now also part of the SERB group. Whilst these 4 companies remain separate, the 2025 UK disclosures for these four companies are being disclosed under the current existing disclosure portal for Veriton Pharma Ltd, for transparency to ensure all data is easily accessible and displayed clearly in one place.

2.3 Excluded ToVs

None

2.4 ToVs Date

This report covers the disclosure ToV from 1st January 2025 to 31st December 2025.

2.5 Direct ToVs

Fee for service, e.g. speaker at meetings, advisor at advisory board meeting.

2.6 Indirect ToVs

Via 3rd part organisations , e.g. Sponsorship of meetings, sponsorship of attendance at conferences

2.7 Non-monetary ToV

None

2.8 ToVs in case of partial attendances or cancellation and refund

None

2.9 Cross border activities

All recorded

2.10 Research and Development (R&D)

Outline Research and Development Transfers of Value to HCPs or HCOs related to the planning or conduct of

- non-clinical studies (as defined in OECD Principles on Good Laboratory Practice).
- clinical trials (as defined in Directive 2001/20/EC); or
- non-interventional studies (NIS) that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study.

Composition of R&D Transfer of Value

The aggregate R&D Transfer of Value includes:

- Contribution to costs of Investigator Meetings and Committees
- Investigator fees for patient visits paid directly to clinical trial site staff or to CROs as an intermediary. Delayed or preliminary payments by CROs to clinical trial site staff are not considered.

Other points to note:

- The aggregate R&D Transfer of Value does not include fees paid to Clinical Research Organisations (CROs).

2.11 Voluntary Disclosure

Not included

3. Specific considerations

3.1 Country unique identifier

None used

3.2 Self incorporated HCP

Where an HCP or ORDM runs a private company, Veriton companies will treat this as if it were an individual HCP/ORDM and will disclose against the individual.

3.3 Multi-year agreements

None

3.4 country specificities

No UK specific disclosures (e.g. No Collaborative Working projects to disclose)

3.5 Quality Check

Internal SERB checks on the data including Marketing, Medical and Legal teams.

4. Data protection legal basis

4.1 Consent collection

Management of consent disclosure for HCPs/ORDMs:

In line with the requirements of the Data Protection Act and the rights of data subject thereunder, Veriton Pharma companies will only make disclosure of an individual HCP's or ORDMs personal data to the ABPI with the prior written consent of the HCP/ORDM concerned.

4.2 Legitimate interests

Veriton Pharma companies records consent by asking those HCPs and ORDMs engaged or sponsored by the company to consider signing and returning an agreement which includes a section for public disclosure. Once returned to Veriton Pharma company the agreement is held electronically for at least 3 calendar years unless such HCP/ORDM notifies the company of their wish to subsequently withdraw their consent during this time.

Each HCP/ORDM is entitled to withdraw their consent to disclosure at any time. In such cases, HCPs and ORDMs are asked to send an email to info@veritonpharma.com, notifying the company that they wish to withdraw their consent for the current calendar reporting period. Following publication of Veriton's ToV data, HCPs and ORDMs are also able to contact the ABPI to withdraw their consent.

5. Form of disclosure

5.1 Date of Publication

March 2026

5.2 Disclosure platform

Disclosure UK – www.disclosureuk.org.uk

5.3 Disclosure language

English

6. Disclosure Financial data

6.1 Currency

GBP

6.2 VAT

Not included

6.3 Calculations rules

Not applicable

7. Additional information

None applicable